Evidence map›Paper›PMID 34900722›Full record

ArticleFrontiers in oncology2021

Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study.

Marie-Christina Jahreiß, Wilma D Heemsbergen, Bo van Santvoort, Mischa Hoogeman, Maarten Dirkx, Floris J Pos, Tomas Janssen, Andre Dekker, Ben Vanneste, Andre Minken and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Marie-Christina JahreißDepartment of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Wilma D HeemsbergenDepartment of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Bo van SantvoortDepartment of Research, Netherlands Comprehensive Cancer Organization, Utrecht, Netherlands.
Mischa HoogemanDepartment of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Maarten DirkxDepartment of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Floris J PosThe Netherlands Cancer Institute, Radiation Oncology, Amsterdam, Netherlands.
Tomas JanssenThe Netherlands Cancer Institute, Radiation Oncology, Amsterdam, Netherlands.
Andre DekkerDepartment of Radiation Oncology (Maastro), GROW Institute for Oncology and Developmental Biology, Maastricht, Netherlands.
Ben VannesteDepartment of Radiation Oncology (Maastro), GROW Institute for Oncology and Developmental Biology, Maastricht, Netherlands.
Andre MinkenDepartment of Radiation Oncology, Radiotherapiegroep, Deventer, Netherlands.
Carel HoekstraDepartment of Radiation Oncology, Radiotherapiegroep, Deventer, Netherlands.
Robert J SmeenkDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Inge M van OortDepartment of Urology, Radboud University Medical Center, Nijmegen, Netherlands.
Chris H BangmaDepartment of Urology, Erasmus University Medical Center, Rotterdam, Netherlands.
Luca IncrocciDepartment of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Katja K H AbenDepartment of Research, Netherlands Comprehensive Cancer Organization, Utrecht, Netherlands.
Erasmus MC Cancer Institute · NLMaastro Clinic · NLRadboud University Nijmegen · NLRadiotherapie Groep · NLThe Netherlands Cancer Institute · NLErasmus MC · NLNetherlands Comprehensive Cancer Organisation · NLRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExternal Beam Radiotherapy (EBRT) techniques dramatically changed over the years. This may have affected the risk of radiation-induced second primary cancers (SPC), due to increased irradiated low dose volumes and scatter radiation. We investigated whether patterns of SPC after EBRT have changed over the years in prostate cancer (PCa) survivors. MATERIALS AND

methodsPCa survivors diagnosed between 1990-2014 were selected from the Netherlands Cancer Registry. Patients treated with EBRT were divided in three time periods, representing 2-dimensional Radiotherapy (RT), 3-dimensional conformal RT (3D-CRT), and the advanced RT (AdvRT) era. Standardized incidence ratios (SIR) and absolute excess risks (AER) were calculated to estimate relative and excess absolute SPC risks. Sub-hazard ratios (sHRs) were calculated to compare SPC rates between the EBRT and prostatectomy cohort. SPCs were categorized by subsite and anatomic region.

resultsPCa survivors who received EBRT had an increased risk of developing a solid SPC (SIR=1.08; 1.05-1.11), especially in patients aged <70 years (SIR=1.13; 1.09-1.16). Pelvic SPC risks were increased (SIR=1.28; 1.23-1.34), with no obvious differences between the three EBRT eras. Non-pelvic SPC were only significantly increased in the AdvRT era (SIR=1.08; 1.02-1.14), in particular for the 1-5 year follow-up period. Comparing the EBRT cohort to the prostatectomy cohort, again an increased pelvic SPC risk was found for all EBRT periods (sHRs= 1.61, 1.47-1.76). Increased non-pelvic SPC risks were present for all RT eras and highest for the AdvRT period (sHRs=1.17, 1.06-1.29).

conclusionSPC risk in patients with EBRT is increased and remained throughout the different EBRT eras. The risk of developing a SPC outside the pelvic area changed unfavorably in the AdvRT era. Prolonged follow-up is needed to confirm this observation. Whether this is associated with increased irradiated low-dose volumes and scatter, or other changes in clinical EBRT practice, is the subject of further research.

Indexed as

advanced external beam radiotherapyprostate cancersecond primary cancersurvivorshipthree-dimensional conformal radiotherapy

Identifiers

PMID34900722
PMCPMC8662556
OpenAlexW3215884450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.